The probiotic strains used in GENESTRA HMF Baby B and HMF Baby F probiotic formulas were evaluated in a recent clinical trial.
Key findings from the 2014 placebo-controlled clinical trial conducted by Allen et al. showed that probiotic supplementation in babies from birth to 6 months reduced skin prick sensitivity to common food allergens by 44 percent and reduced atopic eczema by 57 percent.
Additionally, a 2010 safety study conducted by Allen et al., found that the usage of these probiotic strains did not increase adverse event incidence, number of visits to the doctor, and did not have a negative impact on mothers’ assessment of infant health. Based on these findings, the authors concluded that usage of the probiotic formula was safe during early infancy.
“A healthy gut flora plays an important role in early immune stimulation, and variations in gut colonization at early ages have been associated with the development of atopic disease such as eczema,” said Dr. Nigel Plummer, key research contributor at GENESTRA BRANDS. “Our new HMF Baby probiotic supplements support early colonization of bacteria in an infant’s gut to reduce incidence of skin sensitivity.”
According to the Canadian Dermatology Association, it is estimated that up to 17 percent of Canadians suffer from Atopic Dermatitis at some point in their lives, and it usually starts in infants and young children. HMF Baby B and HMF Baby F both provide Lactobacillus and Bifidobacterium – two of the most common categories of probiotic bacteria that tend to be lower in infants with atopic dermatitis or skin sensitivity.
HMF probiotics are proprietary, non-pathogenic, human-sourced microflora bacterial strains that exhibit strong epithelial adherence and a naturally high tolerance to stomach acid. The HMF Baby supplements are available in a powder format that dissolves easily into breast milk, formula or water and are free of gluten and soy.
